Open-label, Parallel-group, Drug-drug Interaction Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Immunoglobulins (Primary) ; Tesidolumab (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 02 Aug 2017 Status changed from recruiting to completed.
- 01 Jun 2017 Planned End Date changed from 1 May 2017 to 11 Aug 2017.
- 01 Jun 2017 Planned primary completion date changed from 1 May 2017 to 11 Aug 2017.